Top

James W. Welsh, M.D.

Department of Thoracic Radiation Oncology, Division of Radiation Oncology

About Dr. Welsh

Dr. Welsh had a singular focus in life to help humanity, and during his college years he became intrigued by the power of the immune system and astonished that cancer cells could adapt by evading immune detection. This interest led to his first job at Genentech, where he witnessed the development of some of the first targeted therapies, including trastuzumab (Herceptin). During this time, Dr. Welsh first learned of antibody-dependent cellular immunity and how a drug like trastuzumab could be used to influence an immunologic response. During his residency in Radiation Oncology, Dr. Welsh began to realize that radiation has the ability to stimulate immune responses by killing cancer cells within the patient and that process can produce an immunologic T-cell response. Also during his residency, Dr. Welsh ran a lab that led to a patent on a novel c-Met kinase inhibitor, which was licensed to industry. Although it was rewarding to see a drug he developed enter into clinical use, Dr. Welsh came to realize that blocking a single part of a signaling pathway was too simplistic an approach in cancer and could in fact facilitate treatment resistance. Thinking there must be a better way, he began to consider combining radiation therapy with immunotherapy as a potential opportunity to permanently control cancer. In his current position as a tenured Associate Professor at MD Anderson Cancer Center, Dr. Welsh realizes his mission on a daily basis. Seeing first-hand the devastation that cancer causes only serves to galvanize his determination. As an independent investigator, Dr. Welsh is now focused on enhancing the effects of immunotherapy through its rational combination with radiation. This work includes running many of the first trials of anti-CTLA-4 and anti-PD1 with radiation, as well as testing preclinical models of immunotherapy with radiation. Running a lab in addition to treating patients provides a unique clinical insight that comes from seeing firsthand how best to combine immunotherapies with radiation, with the ultimate goal of developing truly personalized therapeutic approaches.

Primary Appointment

Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2003	Dartmouth School of Medicine, Hanover, NH, USA, MD, Medicine
1997	University of California, Davis, CA, USA, BS, Genetics

Postgraduate Training

2004-2008	Clinical Residency, Radiation Oncology, The University of Arizona Health Sciences Center, Tucson, AZ
2003-2004	Clinical Internship, Internal Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH

Board Certifications

2009	American Board of Radiology, Radiation Oncology

Experience & Service

Academic Appointments

Associate Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2021

Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2014

Other Appointments/Responsibilities

Research Associate, Dartmouth Hitchcock Medical Center, Lebanon, NH, 2003 - 2003

Research Associate, Division of Molecular Oncology, Genentech, Inc, San Francisco, CA, 1997 - 1999

Research Assistant, University of California Davis Medical School, Davis, CA, 1996 - 1997

Institutional Committee Activities

Board Member, Center for Professional Development and Entrepreneurship Board of Advisors, 2013 - 2018

Member, Medical Practice Committee, 2012 - 2014

Member, American Society of Radiation Oncology Research Evaluation, 2009 - Present

Consultantships

Scientific Advisor, Pfizer, Inc, New York, NY, 2013 - 2018

Scientific Advisor, RefleXion Medical, San Francisco, CA, 2011 - Present

Scientific Advisor, Ventana Medical, Tucson, AZ, 2011 - 2018

Honors & Awards

2018	Robert M. Chamberlain Distinguished Mentor Award, The University of Texas MD Anderson Cancer Center
2016	ASTRO Abstract Award, Annual Meeting Scientific Program Committee of the American Society for Radiation Oncology
2016	Best of ASTRO, Best of ASTRO Program Committee, American Society of Radiation Oncology
2016	Basic/Translational Science Award
2016	Basic/Transnational Science Abstract Award - Radiation and Cancer Biology, ASTRO
2012	Educational Grant, Hiroshima International Council for Health Care of the Radiation-Exposed (HICARE), Hiroshima International Council for Health Care
2009	Honorarium and Plaque, American College of Veterinary Radiation
2009	Honorarium, Texas Radiological Society
2009	Best of ASTRO Award, Media Feature, American Society of Radiation Oncology
2008	Honorarium, Chicago Multidisciplinary Symposium in Thoracic Oncology, American Society of Radiation Oncology
2007	Methods in Clinical Cancer Research Award, American Society of Clinical Oncology
2007	Roentgen Resident/Fellow Research Award, Radiological Society of North America
2007	Translational Research Symposium Travel Grant, American Society of Radiation Oncology
2007	Annual Meeting Travel Grant Award, American Society of Radiation Oncology
2006	First Place Abstract, Los Angeles Radiological Society Annual Meeting
2006	Best of American Brachytherapy Society, American Brachytherapy Society
2006	Travel Grant Award, American Brachytherapy Society
2006	Best of ASTRO Translational Research Symposium, American Society of Radiation Oncology
2006	Excellence in Scientific Publishing, American Brachytherapy Society
2006	Translational Research Symposium Travel Grant, American Society of Radiation Oncology
2006	International Conference of Translational Radiotherapy Travel Honorarium, Cytyc, Inc
2006	European Organization for Research and Treatment of Cancer Research and Travel Award, SuperGen
2005	Translational Research Symposium Travel Grant, American Society of Radiation Oncology

Professional Memberships

American Society of Radiation Oncology

Member, Research Evaluation Committee of the Science Council, 2012 - Present

American Association for Cancer Research

Member, 2009 - Present

Radiation Therapy Oncology Group

Member, 2009 - Present

Radiological Society of North America

Member, 2009 - Present

American Society of Radiation Oncology

Member, 2008 - Present

American Society of Clinical Oncology

Member, 2008 - Present

American Radium Society

Member, 2006 - Present

Selected Publications

Peer-Reviewed Articles

He K, Hong DS, Ke D, Kebriaei P, Wang T, Danesi H, Bertolet G, Leuschner C, Puebla-Osorio N, Voss TA, Lin Q, Norry E, Fracasso PM, Welsh JW. Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report. Melanoma Res 33(4):332-337, 2023. e-Pub 2023. PMID: 37325860.
He K, Hong DS, Tang C, Sezen D, Cox L, Maleki A, Bertolet G, Nguyen QN, Comeaux NI, Schuda L, Chen D, Welsh JW. Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease. Radiother Oncol 183:109618, 2023. e-Pub 2023. PMID: 36921766.
Barsoumian HB, He K, Hsu E, Bertolet G, Sezen D, Hu Y, Riad TS, Cortez MA, Welsh JW. NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model. Cancer Immunol Immunother. e-Pub 2023. PMID: 37289257.
Hu Y, Paris S, Sahoo N, Bertolet G, Wang Q, Wang Q, Barsoumian HB, Da Silva J, Huang A, Doss DJ, Pollock DP, Hsu E, Selene N, Leyton CSK, Voss TA, Masrorpour F, Ganjoo S, Leuschner C, Pietz JT, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection. JCI Insight 8(12), 2023. e-Pub 2023. PMID: 37345658.
He K, Barsoumian HB, Puebla-Osorio N, Hu Y, Sezen D, Wasley MD, Bertolet G, Zhang J, Leuschner C, Yang L, Kettlun Leyton CS, Fowlkes NW, Green MM, Hettrick L, Chen D, Masrorpour F, Gu M, Maazi H, Revenko AS, Cortez MA, Welsh JW. Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer. Cancer Immunol Res 11(4):486-500, 2023. PMID: 36700864.
Barsoumian HB, He K, Hsu E, Bertolet G, Sezen D, Hu Y, Cortez MA, Welsh JW. NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model. Res Sq, 2023. e-Pub 2023. PMID: 36824846.
Barsoumian HB, Sheth RA, Ramapriyan R, Hsu E, Gagea M, Crowley K, Sezen D, Williams M, Welsh JW. Radiation Therapy Modulates Tumor Physical Characteristics to Reduce Intratumoral Pressure and Enhance Intratumoral Drug Delivery and Retention. Adv Radiat Oncol 8(2):101137, 2023. e-Pub 2022. PMID: 36632088.
Ganjoo S, Gupta P, Corbali HI, Nanez S, Riad TS, Duong LK, Barsoumian HB, Masrorpour F, Jiang H, Welsh JW, Cortez MA. The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy. Front Immunol 14:1172931, 2023. e-Pub 2023. PMID: 37180129.
Duong LK, Corbali HI, Riad TS, Ganjoo S, Nanez S, Voss T, Barsomium H, Welsh J, Cortez MA. Lipid metabolism in tumor immunology and immunotherapy. Front Oncol 13:1187279, 2023. e-Pub 2023. PMID: 37205182.
Gregucci F, Spada S, Barcellos-Hoff MH, Bhardwaj N, Chan Wah Hak C, Fiorentino A, Guha C, Guzman ML, Harrington K, Herrera FG, Honeychurch J, Hong T, Iturri L, Jaffee E, Karam SD, Knott SRV, Koumenis C, Lyden D, Marciscano AE, Melcher A, Mondini M, Mondino A, Morris ZS, Pitroda S, Quezada SA, Santambrogio L, Shiao S, Stagg J, Telarovic I, Timmerman R, Vozenin MC, Weichselbaum R, Welsh J, Wilkins A, Xu C, Zappasodi R, Zou W, Bobard A, Demaria S, Galluzzi L, Deutsch E, Formenti SC. Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference. Oncoimmunology 12(1):2222560, 2023. e-Pub 2023. PMID: 37363104.
Verma V, Yegya-Raman N, Sprave T, Han G, Kantarjian HM, Welsh JW, Chang JY, Lin SH. A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases. Int J Radiat Oncol Biol Phys 114(5):977-988, 2022. e-Pub 2022. PMID: 35675852.
Kim H, Venkatesulu BP, McMillan MT, Verma V, Lin SH, Chang JY, Welsh JW. Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials. Int J Radiat Oncol Biol Phys 114(4):676-683, 2022. e-Pub 2022. PMID: 35973624.
Hu Y, Paris S, Bertolet G, Barsoumian HB, He K, Sezen D, Chen D, Wasley M, Silva JD, Mitchell JA, Voss TA, Masrorpour F, Leyton CK, Yang L, Leuschner C, Puebla-Osorio N, Gandhi S, Nguyen QN, Cortez MA, Welsh JW. Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer. J Nanobiotechnology 20(1):417, 2022. e-Pub 2022. PMID: 36123677.
Barsoumian HB, Sezen D, Menon H, Younes AI, Hu Y, He K, Puebla-Osorio N, Wasley M, Hsu E, Patel RR, Yang L, Cortez MA, Welsh JW. High plus low dose radiation strategy in combination with TIGIT and PD1 blockade to promote systemic antitumor responses. Cancers (Basel) 14(1):221, 2022. e-Pub 2022. PMID: 35008385.
Sezen D, Barsoumian HB, He K, Hu Y, Wang Q, Abana CO, Puebla-Osorio N, Hsu EY, Wasley M, Masrorpour F, Wang J, Cortez MA, Welsh JW. Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. Front Immunol 13:984318, 2022. e-Pub 2022. PMID: 36275767.
Seyedin SN, Bassalow R, Mawlawi OR, Turner LM, Patel RR, Mazin SR, Oderinde OM, Voronenko Y, Wages CA, Olcott PD, Chang JY, Balter PA, Welsh JW. The potential of biology-guided radiation therapy in thoracic cancer: A preliminary treatment planning study. Front Oncol 12:921473, 2022. e-Pub 2022. PMID: 36313653.
Ganjoo S, Puebla-Osorio N, Nanez S, Hsu E, Voss T, Barsoumian H, Duong LK, Welsh JW, Cortez MA. Bone morphogenetic proteins, activins, and growth and differentiation factors in tumor immunology and immunotherapy resistance. Front Immunol 13:1033642, 2022. e-Pub 2022. PMID: 36353620.
Hu Y, Paris S, Bertolet G, Barsoumian HB, Wang Q, Da Silva J, Patel NB, Nguyen N, Doss DJ, Huang A, Hsu E, Leyton CSK, Voss TA, Masrorpour F, Leuschner C, Pietz JT, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model. Front Immunol 13:1022011, 2022. e-Pub 2022. PMID: 36405757.
Hu Y, Paris S, Barsoumian H, Abana CO, He K, Sezen D, Wasley M, Masrorpour F, Chen D, Yang L, Dunn JD, Gandhi S, Nguyen QN, Cortez MA, Welsh JW. A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model. J Nanobiotechnology 19(1):416, 2021. e-Pub 2021. PMID: 34895262.
Hu Y, Paris S, Barsoumian H, Abana CO, He K, Wasley M, Younes AI, Masrorpour F, Chen D, Yang L, Dunn JD, Zhang J, Gandhi S, Nguyen QN, Cortez MA, Welsh J. Radiotherapy enhanced by NBTXR3 nanoparticles overcomes anti-PD1 resistance and evokes abscopal effects. Int J Radiat Oncol Biol Phys 111(3):647-657, 2021. e-Pub 2021. PMID: 34242713.
Shang S, Liu J, Verma V, Wu M, Welsh J, Yu J, Chen D. Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates. Cancer Commun (Lond) 41(11):1086-1099, 2021. e-Pub 2021. PMID: 34658186.
Butner JD, Martin GV, Wang Z, Corradetti B, Ferrari M, Esnaola N, Chung C, Hong DS, Welsh JW, Hasegawa N, Mittendorf EA, Curley SA, Chen SH, Pan PY, Libutti SK, Ganesan S, Sidman RL, Pasqualini R, Arap W, Koay EJ, Cristini V. Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. Elife 10. e-Pub 2021. PMID: 34749885.
Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, Lin SH, O'Reilly MS, Jeter MD, Balter PA, McRae SE, Berry D, Heymach JV, Roth JA, STARS Lung Cancer Trials Group. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol 22(10):1448-1457, 2021. e-Pub 2021. PMID: 34529930.
Metzger A, Appiah A, Wright C, Jairam C, Amini A, Park H, Welsh JW, Thomas C, Verma V, Ludmir E. Financial Relationships Between Industry and Principal Investigators of United States Cooperative Group Randomized Cancer Clinical Trials. International Journal of Cancer 149(9):1683-1690, 2021.
Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: results of a phase II trial. Radiother Oncol 162:60-67, 2021. e-Pub 2021. PMID: 34237343.
Sezen D, Verma V, He K, Abana CO, Barsoumian H, Ning MS, Tang C, Hurmuz P, Puebla-Osorio N, Chen D, Tendler I, Comeaux N, Nguyen QN, Chang JY, Welsh JW. Considerations for clinical trials testing radiotherapy combined with immunotherapy for metastatic disease. Semin Radiat Oncol 31(3):217-226, 2021. PMID: 34090648.
Sezen D, Patel RR, Tang C, Onstad M, Nagarajan P, Patel SP, Welsh JW, Lin LL. Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma. Gynecol Oncol 161(3):645-652, 2021. e-Pub 2021. PMID: 33795130.
Jing W, Liu Y, Zhu H, Welsh J, Gandhi S, Jeter M, Nguyen Q, Chen AB, O'Reilly M, Liao Z, Chang JY, Lee P, Lin SH. Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. Clin Transl Radiat Oncol 28:54-61, 2021. e-Pub 2021. PMID: 33778173.
Butner JD, Wang Z, Elganainy D, Al Feghali KA, Plodinec M, Calin GA, Dogra P, Nizzero S, Ruiz-Ramírez J, Martin GV, Tawbi HA, Chung C, Koay EJ, Welsh JW, Hong DS, Cristini V. A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden. Nat Biomed Eng 5(4):297-308, 2021. e-Pub 2021. PMID: 33398132.
Chen D, Patel RR, Verma V, Ramapriyan R, Barsoumian HB, Angelica Cortez M, Welsh JW. Corrigendum to "Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy" [Radiother Oncol 150 (2020) 114-120]. Radiother Oncol. e-Pub 2021. PMID: 33714536.
He K, Barsoumian HB, Sezen D, Puebla-Osorio N, Hsu EY, Verma V, Abana CO, Chen D, Patel RR, Gu M, Cortez MA, Welsh JW. Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer. Front Oncol 11:737425, 2021. e-Pub 2021. PMID: 34497773.
Wu L, Zhu J, Rudqvist NP, Welsh J, Lee P, Liao Z, Xu T, Jiang M, Zhu X, Pan X, Li P, Zhou Z, He X, Yin R, Feng J. T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer. Front Immunol 12:719285, 2021. e-Pub 2021. PMID: 34733273.
Welsh JW, Heymach JV, Guo C, Menon H, Klein K, Cushman TR, Verma V, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Comeaux N, Patel RR, Chen D, Ozgen T, Nguyen QN, Chang JY, Altan M, Zhang J, Papadimitrakopoulou VA, Simon GR, Byers LA, Glisson B. Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. J Thorac Oncol 15(12):1919-1927, 2020. e-Pub 2020. PMID: 32916308.
Siu LL, Brody J, Gupta S, Marabelle A, Jimeno A, Munster P, Grilley-Olsen JE, Rook AH, Hollebecque A, Wong RKS, Welsh JW, Wu Y, Morehouse C, Hamid O, Walcott F, Zooper ZA, Kumar R, Ferté C, Hong DS. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. e-Pub 2020.
Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, Hess K, de Groot P, Nguyen QN, Varghese R, Comeaux NI, Simon G, Skoulidis F, Chang JY, Papdimitrakopoulou V, Lin SH, Heymach JV. Pembrolizumab With or Without Radiation Therapy for Metastatic Non-Small Cell Lung Cancer: A Randomized Phase I/II Trial. J Immunother Cancer 8(2), 2020. PMID: 33051340.
Barsoumian HB, Ramapriyan R, Younes AI, Caetano MS, Menon H, Comeaux NI, Cushman TR, Schoenhals JE, Cadena AP, Reilly TP, Chen D, Masrorpour F, Li A, Hong DS, Diab A, Nguyen QN, Glitza I, Ferrarotto R, Chun SG, Cortez MA, Welsh J. Low dose radiation treatment enhances systemic anti-tumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer 8(2), 2020. PMID: 33106386.
Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot PM, Nguyen QN, Comeaux NI, Simon GR, Skoulidis F, Lin SH, He K, Patel R, Heymach J, Baas P, Welsh JW. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. e-Pub 2020. PMID: 33096027.
Chen D, Verma V, Patel RR, Barsoumian HB, Cortez MA, Welsh JW. Absolute lymphocyte count predicts abscopal responses and outcomes in patients receiving combined immunotherapy and radiotherapy: a prospective-retrospective analysis of 3 phase I/II trials. Int J Radiat Oncol Biol Phys 108(1):196-203, 2020. e-Pub 2020. PMID: 32036004.
Cortez MA, Masrorpour F, Ivan C, Zhang J, Younes AI, Lu Y, Estecio MR, Barsoumian HB, Menon H, Caetano MDS, Ramapriyan R, Schoenhals JE, Wang X, Skoulidis F, Wasley MD, Calin G, Hwu P, Welsh JW. Bone morphogenetic protein 7 promotes resistance to immunotherapy. Nat Commun 11(1):4840, 2020. e-Pub 2020. PMID: 32973129.
Xie X, Lin SH, Welsh JW, Wei X, Jin H, Mohan R, Liao Z, Xu T. Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes. Radiother Oncol 154:187-193. e-Pub 2020. PMID: 32916236.
Patel RR, Verma V, Barsoumian H, Ning MS, Chun SG, Tang C, Chang JY, Lee PP, Gandhi S, Balter P, Dunn JD, Chen D, Puebla-Osorio N, Cortez AM, Welsh JW. Use of Multi-Site Radiation Therapy as Systemic Therapy: A New Treatment Approach Personalized by Patient Immune Status. Int J Radiat Oncol Biol Phys. e-Pub 2020. PMID: 32798606.
Ayoub Z, Ning MS, Brooks ED, Kang J, Welsh JW, Chen A, Gandhi S, Heymach JV, Vaporciyan AA, Chang JY. Definitive management of presumed synchronous early-stage non-small cell lung cancers: outcomes and utility of stereotactic ablative radiotherapy. Int J Radiat Oncol Biol Phys 107(2):261-269, 2020. PMID: 32044413.
Chen D, Barsoumian HB, Fischer GM, Yang L, Verma C, Younes AI, Hu Y, Masrorpour F, Klein K, Vellano CP, Marzalek JR, Davies MA, Cortez MA, Welsh JW. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor. J ImmunoTher. e-Pub 2020.
Chen D, Patel RR, Verma V, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Welsh JW. Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in patients receiving combined immunotherapy and radiotherapy. Green Journal, 2020.
Seyedin SM, Gannon MK, Plichta KA, Abushahin LI, Berg DJ, Arshava EV, Parekh KR, Keech JC, Caster JM, Welsh JW, Allen BG. Safety and Efficacy of Stereotactic Body Radiation Therapy for Locoregional Recurrences after Prior Chemoradiation for Advanced Esophageal Carcinoma. Front Oncol, 2020.
Bunter J, Elganainy D, Wang C, Wang Z, Chen S, Esnaola N, Pasqualini R, Arap W, Hong D, Welsh JW,, Koay E, Cristini V. Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy. Sci Adv 29:6(18):eaay6298, 2020.
Chen D, Barsoumian HB, Yang L, Younes AI, Verma V, Hu Y, Menon H, Wasley M, Masropour F, Mosaffa S, Ozgen T, Klein K, Cortez MA, Welsh JW. SHP-2 and PD-L1 inhibition combined with radiotherapy enhances systemic antitumor effects in an anti-PD-1-resistant model of non-small-cell lung cancer. Cancer Immunol Res. e-Pub 2020.
Pezzi TA, Schwartz DL, Pisters KMW, Mohamed ASR, Welsh JW, Chang JY, Liao Z, Gandhi SJ, Byers LA, Minsky BD, Fuller CD, Chun SG. Association of Medicaid insurance with survival among patients with small cell lung cancer. JAMA Open 3(4):e203277, 2020. PMID: 32320035.
Pasalic D, Betancourt-Cuellar SL, Taku N, Ludmir EB, Lu Y, Allen PK, Tang C, Antonoff MB, Fuller CD, Rosenthal DI, Morrison WH, Phan J, Garden AS, Welsh JW, Chang JY, Liao Z, Erasmus JJ, Nguyen QN. Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head Neck. e-Pub 2020. PMID: 32129548.
Welsh JW, Heymach JV, Chen D, Verma V, Cushman TR, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Menon H, Nguyen QN, Chang JY, Altan M, Papadimitrakopoulou VA, Simon GR, Raju U, Byers L, Glisson B. Phase I trial of pembrolizumab and radiation therapy after induction chemotherapy for extensive-stage small cell lung cancer. J Thorac Oncol 15(2):266-273, 2020. PMID: 31605794.
Pasalic D, Lu Y, Betancourt-Cuellar SL, Taku N, Mesko SM, Bagley AF, Chance WW, Allen PK, Tang C, Antonoff MB, Balter PA, Mehran RJ, Welsh JW, Liao Z, Gomez D, Erasmus JJ, Nguyen QN. Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure. Radiother Oncol 145:178-185, 2020. PMID: 32044530.
Chen D, Menon H, Verma V, Guo C, Ramapriyan R, Barsoumian H, Younes A, Hu Y, Wasley M, Cortez MA, Welsh JW. Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials. J Immunother Cancer 8(1), 2020. PMID: 31996395.
Klein K, He K, Younes AI, Barsoumian HB, Chen D, Ozgen T, Mosaffa S, Patel RR, Gu M, Novaes J, Narayanan A, Cortez MA, Welsh JW. Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches. Front Immunol 11:573326, 2020. e-Pub 2020. PMID: 33178201.
Caetano MS, Younes AI, Barsoumian HB, Quigley M, Menon H, Gao C, Spires T, Reilly TP, Cadena AP, Cushman TR, Schoenhals JE, Li A, Nguyen QN, Cortez MA, Welsh JW. Triple therapy with Mertk and PD1 inhibition plus radiotherapy promotes abscopal antitumor immune responses. Clin Cancer Res 25(24):7576-7584, 2019. PMID: 31540976.
Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS. Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation-related abscopal responses. Cancer Immunol Res 7(12):1903-1909, 2019. PMID: 31658994.
Menon H, Chen D, Ramapriyan R, Verma V, Barsoumian HB, Cushman TR, Younes AI, Cortez MA, Erasmus JJ, de Groot P, Carter BW, Hong DS, Glitza IC, Ferrarotto R, Altan M, Diab A, Chun SG, Heymach JV, Tang C, Nguyen QN, Welsh JW. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J Immunother Cancer 7(1):237, 2019. PMID: 31484556.
Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, Nguyen QN, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Barsoumian HB, Erasmus JJ, Lee JH, Bhutani MS, Hess KR, Minsky BD, Welsh JW. Results of a phase 1/2 trial of chemoradiotherapy with simultaneous integrated boost of radiotherapy dose in unresectable locally advanced esophageal cancer. JAMA Oncol 17(5(11)):1597-1604, 2019. PMID: 31529018.
Verma V, Ludmir EB, Mesko SM, Brooks ED, Augustyn A, Milano MT, Lin SH, Chang JY, Welsh JW. Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies. Pract Radiat Oncol. e-Pub 2019. PMID: 31446147.
Elhammali A, Blanchard P, Yoder A, Liao Z, Zhang X, Ronald Zhu X, Allen PK, Jeter M, Welsh JW, Nguyen QN. Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. Radiother Oncol 136:136-142, 2019. PMID: 31015115.
Cadena AP, Cushman TR, Welsh JW. Glycosylation and antitumor immunity. Int Rev Cell Mol Biol 343:111-127, 2019. PMID: 30712671.
Li A, Barsoumian HB, Schoenhals JE, Caetano MS, Wang X, Menon H, Valdecanas DR, Niknam S, Younes AI, Cortez MA, Welsh JW. IDO1 inhibition overcomes radiation-induced "rebound immune suppression" by reducing numbers of IDO1-expressing myeloid-derived suppressor cells in the tumor microenvironment. Int J Radiat Oncol Biol Phys 104(4):903-912, 2019. PMID: 30905636.
Nguyen QN, Chun SG, Chow E, Komaki R, Liao Z, Zacharia R, Szeto BK, Welsh JW, Hahn SM, Fuller CD, Moon BS, Bird JE, Satcher R, Lin PP, Jeter M, O'Reilly MS, Lewis VO. Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 trial. JAMA Oncol 5(6):872-878, 2019. PMID: 31021390.
Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol 37(18):1558-1565, 2019. PMID: 31067138.
Barsoumian HB, Younes SI, Ramapriyan R, Caetano MS, Schoenhals JE, Menon H, Cushman TR, Cadena A, Li A, Cortez MA and Welsh JW. Low dose radiotherapy promotes immune-mediated anti-tumor responses. J Immunol 202(1). e-Pub 2019.
Cortez MA, Anfossi S, Ramapriyan R, Menon H, Atalar SC, Aliru M, Welsh JW, Calin GA. Role of miRNAs in Immune Responses and Immunotherapy in Cancer. Genes Chromosomes Cancer 58(4):244-253, 2019. PMID: 30578699.
Bloom BC, Augustyn A, Pezzi TA, Menon H, Mayo LL, Shah SJ, Schwartz DL, Chmura SJ, Johnson FM, Welsh JW, Chun SG. Rescue of immunotherapy-refractory metastatic merkel cell carcinoma with conventionally fractionated radiotherapy and concurrent pembrolizumab. Front Oncol 9:223, 2019. PMID: 31024834.
Ramapriyan R, Caetano MS, Barsoumian HB, Mafra ACP, Zambalde EP, Menon H, Tsouko E, Welsh JW, Cortez MA. Altered cancer metabolism in mechanisms of immunotherapy resistance. Pharmacol Ther 195:162-171, 2019. PMID: 30439456.
Verma V, Haque W, Cushman TR, Lin C, Simone CB, Chang JY, McClelland S, Welsh JW. Racial and insurance-related disparities in delivery of immunotherapy-type compounds in the United States. J Immunother 42(2):55-64, 2019. PMID: 30628924.
Menon H, Ramapriyan R, Cushman TR, Verma V, Kim HH, Schoenhals JE, Atalar C, Selek U, Chun SG, Chang JY, Barsoumian HB, Nguyen QN, Altan M, Cortez MA, Hahn SM, Welsh JW. Role of radiation therapy in modulation of the tumor stroma and microenvironment. Front Immunol 10:193, 2019. PMID: 30828330.
Solanki AA, Bossi A, Efstathiou JA, Lock D, Mondini M, Ramapriyan R, Welsh JW, Kang J. Combining immunotherapy with radiotherapy for the treatment of genitourinary malignancies (review). Eur Urol Oncol 2(1):79-87, 2019. PMID: 30929848.
Suzuki R, Wei X, Allen PK, Welsh JW, Cox JD, Komaki R, Lin SH. Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung cancer: a retrospective analysis. Radiat Oncol 13(1):258, 2018. e-Pub 2018. PMID: 30594213.
Suzuki R, Wei X, Allen PK, Welsh JW, Cox JD, Komaki R, Lin SH. Twice-daily thoracic radiotherapy for limited-stage small cell lung cancer does not increase the incidence of acute severe esophagitis. Clin Lung Cancer 19(6):e885-e891, 2018. PMID: 30197263.
Niknam S, Barsoumian HB, Schoenhals JE, Jackson HL, Yanamandra N, Caetano MS, Li A, Younes AI, Cadena A, Cushman TR, Chang JY, Nguyen QN, Gomez DR, Diab A, Heymach JV, Hwu P, Cortez MA, Welsh JW. Radiation followed by OX40 stimulation drives local and abscopal antitumor effects in an anti-PD1-resistant lung tumor model. Clin Cancer Res 24(22):5735-5743, 2018. PMID: 29784675.
Dorta-Estremera S, Colbert LE, Nookala SS, Yanamandra AV, Yang G, Delgado A, Mikkelson M, Eifel P, Jhingran A, Lilie LL, Welsh JW, Schmeler K, Sastry JK, Klopp A. Kinetics of intratumoral immune cell activation during chemoradiation for cervical cancer. Int J Radiat Oncol Biol Phys 102(3):593-600, 2018. PMID: 30017792.
Verma V, Sprave T, Haque W, Simone C, Chang J, Welsh JW, Thomas C.. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J ImmunoTher Cancer 6(1):128, 2018. PMID: 30470252.
Verma V, Cushman TR, Tang C, Welsh JW. Toxicity of radiation and immunotherapy combinations. Adv Radiat Oncol 3(4):506-511, 2018. PMID: 30370349.
Li A, Barsoumian HB, Schoenhals JE, Cushman TR, Caetano MS, Wang X, Valdecanas DR, Niknam S, Younes AI, Li G, Woodward WA, Cortez MA, Welsh JW. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells. Cancer Lett 431:54-63, 2018. PMID: 29746927.
Schoenhals JE, Cushman TR, Barsoumian HB, Li A, Cadena AP, Niknam S, Younes AI, Caetano MDS, Cortez MA, Welsh JW. Anti-glucocorticoid-induced tumor necrosis factor–related protein (GITR) therapy overcomes radiation-induced Treg immunosuppression and drives abscopal effects. Front Immunol 9:2170, 2018. PMID: 30294332.
Suzuki R, Wei X, Allen PK, Welsh JW, Komaki R, Lin SH. Hematologic variables associated with brain failure in patients with small-cell lung cancer. Radiother Oncol 128(3):505-512, 2018. PMID: 29907337.
Pezzi TA, Schwartz DL, Mohamed ASR, Welsh JW, Komaki RU, Hahn SM, Sepesi B, Pezzi CM, Fuller CD, Chun SG. Barriers to combined modality therapy for limited-stage small cell lung cancer. JAMA Oncol 4(8):e174504, 2018. PMID: 29302695.
Cushman TR, Caetano MS, Welsh JW, Verma V. Overview of Ongoing Clinical Trials Investigating Combined Radiotherapy and Immunotherapy. Immunotherapy 10(10):851-0, 2018. PMID: 30073899.
Brooks ED, Sun B, Feng L, Verma V, Zhao L, Gomez DR, Liao Z, Jeter M, O'Reilly M, Welsh JW, Nguyen QN, Erasmus JJ, Eapen G, Ahrar K, Antonoff MB, Hahn SM, Heymach JV, Rice DC, Chang JY. Association of long-term outcomes and survival with multidisciplinary salvage treatment for local and regional recurrence after stereotactic ablative radiotherapy for early-stage lung cancer. JAMA Netw Open 1(4):e181390, 2018. PMID: 30646121.
Verma V, Cushman TR, Selek U, Tang C, Welsh JW. Safety of combined immunotherapy and thoracic radiation therapy: analysis of 3 single-institutional phase I/II trials. Int J Radiat Oncol Biol Phys 101(5):1141-1148, 2018. PMID: 30012526.
Kim CR, Kim B, Ning MS, Reddy JP, Liao Z, Tang C, Welsh JW, Mott FE, Shih YT, Gomez DR. Cost analysis of PET/CT versus CT as surveillance for stage III non-small-cell lung cancer after definitive radiation therapy. Clin Lung Cancer 19(4):e517-e528, 2018. e-Pub 2018. PMID: 29685701.
Benveniste MF, Welsh J, Viswanathan C, Shroff GS, Betancourt Cuellar SL, Carter BW, Marom EM. Lung cancer: posttreatment imaging: radiation therapy and imaging findings (review). Radiol Clin North Am 56(3):471-483, 2018. PMID: 29622079.
Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C, Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA. Cancer-associated rs6983267 SNP and its accompanying long non-coding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28(4):432-447, 2018. e-Pub 2018. PMID: 29567676.
Suzuki R, Lin SH, Wei X, Allen PK, Welsh JW, Byers LA, Komaki R. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiother Oncol 126(3):499-505, 2018. PMID: 29398150.
Cushman TR, Gomez D, Kumar R, Likacheva A, Chang JY, Cadena AP, Paris S, Welsh JW. Combining radiation plus immunotherapy to improve systemic immune response. J Thorac Dis 10(Suppl 3):S468-S479, 2018. PMID: 29593892.
Aliru ML, Schoenhals JE, Venkatesulu BP, Anderson CC, Barsoumian HB, Younes AI, K Mahadevan LS, Soeung M, Aziz KE, Welsh JW, Krishnan S. Radiation therapy and immunotherapy: what is the optimal timing or sequencing?. Immunotherapy 10(4):299-316, 2018. PMID: 29421979.
Cadena A, Cushman TR, Anderson C, Barsoumian HB, Welsh JW, Cortez MA. Radiation and anti-cancer vaccines: a winning combination. Vaccines (Basel) 6(1), 2018. PMID: 29385680.
Tang C, Hobbs B, Amer A, Li X, Behrens C, Canales JR, Cuentas EP, Villalobos P, Fried D, Chang JY, Hong DS, Welsh JW, Sepesi B, Court L, Wistuba II, Koay EJ. Development of an immune-pathology informed radiomics model for non-small cell lung cancer. Sci Rep 8(1):1922, 2018. PMID: 29386574.
Kono M, Allen PK, Lin SH, Wei X, Jeter MD, Welsh JW, Cox JD, Komaki R. Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival. J Thorac Oncol 12(11):1696-1703, 2017. PMID: 28804012.
An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, Davies MA, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol 125(1):80-88, 2017. PMID: 28916225.
Davuluri R, Jiang W, Fang P, Xu C, Komaki R, Gomez DR, Welsh J, Cox JD, Crane CH, Hsu CC, Lin SH. Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy. Int J Radiat Oncol Biol Phys 99(1):128-135, 2017. PMID: 28816138.
Wang Q, Zhou S, Court LE, Verma V, Koay EJ, Zhang L, Wencheng Z, Tang C, Lin S, Welsh JW, Blum M, Betancourt S, Maru D, Hofstetter WL, Chang JY. Radiomics predicts clinical outcome in primary gastroesophageal junction adenocarcinoma treated by chemo/radiotherapy and surgery. Physics and Imaging in Radiation Oncology 3:37-42, 2017. e-Pub 2017.
Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, Allen PK, Liao Z, Welsh J, Lin SH, Gomez D, Jeter M, O'Reilly M, Zhu RX, Zhang X, Li H, Mohan R, Heymach JV, Vaporciyan AA, Hahn S, Cox JD. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol 3(8):e172032, 2017. PMID: 28727865.
Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, Allen PK, Balter PA, Welsh JW, O'Reilly MS, Gomez D, Hahn SM, Roth JA, Mehran RJ, Heymach JV, Chang JY. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer 123(16):3031-3039, 2017. PMID: 28346656.
Brooks ED, Sun B, Zhao L, Komaki R, Liao Z, Jeter M, Welsh JW, O'Reilly MS, Gomez DR, Hahn SM, Heymach JV, Rice DC, Chang JY. Stereotactic ablative radiation therapy is highly safe and effective for elderly patients with early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 98(4):900-907, 2017. PMID: 28258887.
Chance WW, Nguyen QN, Mehran R, Welsh JW, Gomez DR, Balter P, Komaki R, Liao Z, Chang JY. Stereotactic ablative radiotherapy for adrenal gland metastases: factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. Pract Radiat Oncol 7(3):e195-e203, 2017. e-Pub 2016. PMID: 27743801.
Schoenhals JE, Seyedin SN, Anderson C, Brooks ED, Li YR, Younes AI, Niknam S, Li A, Barsoumian HB, Cortez MA, Welsh JW. Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. Transl Lung Cancer Res 6(2):148-158, 2017. PMID: 28529897.
Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T-cells. Clin Cancer Res 23(6):1-9, 2017. PMID: 27649551.
Logan JK, Tang C, Liao Z, Lee JJ, Heymach JV, Swisher SG, Welsh JW, Zhang J, Lin SH, Gomez DR. Analysis of factors affecting successful clinical trial enrollment in the context of three prospective, randomized, controlled trials. Int J Radiat Oncol Biol Phys 97(4):770-777, 2017. PMID: 28244413.
Reddy JP, Tang C, Shih T, Kim B, Kim C, Nguyen QN, Welsh JW, Benveniste M, Zhang J, Liao Z, Gomez DR. Influence of surveillance PET/CT on detection of early recurrence after definitive radiation in stage III non-small-cell lung cancer. Clin Lung Cancer 18(2):141-148, 2017. PMID: 27913215.
Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, Ajani JA, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Nguyen QN, Minsky BD, Erasmus JJ, Lee JH, Bhutani M, Komaki RU. Local control and toxicity of a simultaneous integrated boost for dose escalation in locally advanced esophageal cancer: interim results from a prospective phase I/II trial. J Thorac Oncol 12(2):375-382, 2017. PMID: 27794500.
Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, Overwijk WW, Gomez DR, Chang JY, Hahn SM, Cortez MA, Welsh JW. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res 77(4):839-850, 2017. PMID: 27821490.
Swanick CW, Allen PK, Tao R, Olanrewaju AM, Sutton JR, Lin SH, Welsh JW, Das P, Chang JY, Crane CH, Gomez DR. Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions. Pract Radiat Oncol 7(1):63-71, 2017. PMID: 27637136.
Tang C, Welsh JW, Hong D. Phase I trial: SABR and ipilimumab-response. Clin Cancer Res 23(1):321, 2017. PMID: 28049161.
Li P, Wang X, Liu Z, Liu H, Xu T, Wang H, Gomez DR, Nguyen QN, Wang LE, Teng Y, Song Y, Komaki R, Welsh JW, Wei Q, Liao Z. Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer. Clin Lung Cancer 17(4):253-262.e5, 2016. PMID: 26732495.
Zhao L, Zhou S, Balter P, Shen C, Gomez DR, Welsh JW, Lin SH, Chang JY. Planning target volume D95 and mean dose should be considered for optimal local control for stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys 95(4):1226-35, 2016. e-Pub 2016. PMID: 27209498.
Brooks ED, Schoenhals JE, Tang C, Micevic G, Gomez DR, Chang JY, Welsh JW. Stereotactic ablative radiation therapy combined with immunotherapy for solid tumors. Cancer J 22(4):257-66, 2016. PMID: 27441745.
Schoenhals JE, Seyedin SN, Tang C, Cortez MA, Niknam S, Tsouko E, Chang JY, Hahn SM, Welsh JW. Preclinical rationale and clinical considerations for radiotherapy plus. Cancer J 22(2):130-7, 2016. PMID: 27111909.
Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, Kelnar K, Martin D, Komaki R, Gomez DR, Krishnan S, Calin GA, Bader AG, Welsh JW. PDL1 regulation by p53 via miR-34. J Natl Cancer Inst 108(1), 2016. PMID: 26577528.
Cortez MA, Valdecanas D, Niknam S, Peltier HJ, Diao L, Giri U, Komaki R, Calin GA, Gomez DR, Chang JY, Heymach JV, Bader AG, Welsh JW. In vivo delivery of miR-34a sensitizes lung tumors to radiation through RAD51 regulation. Mol Ther Nucleic Acids 4:e270, 2015. PMID: 26670277.
Li P, Wang X, Liu Z, Liu H, Xu T, Wang H, Gomez DR, Nguyen QN, Wang LE, Teng Y, Song Y, Komaki R, Welsh JW, Wei Q, Liao Z. Single nucleotide polymorphisms in CBLB, a regulator of T-cell response, predict radiation pneumonitis and outcomes after definitive radiotherapy for non-small-cell lung cancer. Clin Lung Cancer 7304(15):272-277, 2015. PMID: 26732495.
Smith BD, Jiang J, Chang JY, Welsh JW, Likhacheva A, Buchholz TA, Swisher SG, Shirvani SM. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. J Geriatr Oncol 6(4):324-31, 2015. PMID: 26094172.
Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK. Adding erlotinib to chemoradiation improves overall survival but not progression-free survival in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 92(2):317-24, 2015. PMID: 25968826.
Parikh NR, Likhacheva A, Pinnix C, Allen PK, Prabhu SS, Guha-Thakurta N, Welsh JW, Brown PD, Chang EL. Prognostic significance of EGFR and KRAS mutations in NSCLC patients with brain metastases treated radiosurgery. J Radiosurg SBRT 3(3):171-178, 2015. PMID: 29296399.
Swanick CW, Lin SH, Sutton J, Naik NS, Allen PK, Levy LB, Liao Z, Welsh JW, Komaki R, Chang JY, Gomez DR. Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clin Lung Cancer 16(2):156-63, 2015. PMID: 25467928.
Chance WW, Rice DC, Allen PK, Tsao AS, Fontanilla HP, Liao Z, Chang JY, Tang C, Pan HY, Welsh JW, Mehran RJ, Gomez DR. Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys 91(1):149-56, 2015. PMID: 25442335.
Seyedin SN, Tang C, Welsh JW. Author's view: radiation and immunotherapy as systemic therapy for solid tumors. Oncoimmunology 4(3):e986402, 2015. PMID: 25949899.
Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 7(9):967-80, 2015. PMID: 26310908.
Xu T, Liao Z, O'Reilly MS, Levy LB, Welsh JW, Wang LE, Lin SH, Komaki R, Liu Z, Wei Q, Gomez DR. Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. Radiother Oncol 113(3):379-84, 2014. PMID: 25466375.
Welsh JW, Seyedin SN, Cortez MA, Maity A, Hahn SM. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Clin Cancer Res 20(24):6230-2, 2014. PMID: 25348514.
Selek U, Bölükbasi Y, Welsh JW, Topkan E. Intensity-Modulated Radiotherapy versus 3-Dimensional Conformal Radiotherapy Strategies for Locally Advanced Non-Small-Cell Lung Cancer. Balkan Med J 31(4):286-94, 2014. PMID: 25667781.
Shirvani SM, Jiang J, Chang JY, Welsh JW, Likhacheva A, Buchholz TA, Swisher SG, Smith BD. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg 149(12):1244-53, 2014. PMID: 25321323.
Yu WW, Zhu ZF, Fu XL, Zhao KL, Mao JF, Wu KL, Yang HJ, Fan M, Zhao S, Welsh JW. Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma : early results of a phase II study. Strahlenther Onkol 190(11):979-86, 2014. PMID: 24609941.
Gomez DR, Yusuf SW, Munsell MF, Welsh JW, Liao Z, Lin SH, Pan HY, Chang JY, Komaki R, Cox JD, McAleer MF, Grosshans DR. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol 9(10):1554-60, 2014. PMID: 25521400.
Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal JD, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Jones S, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5:5241, 2014. PMID: 25348003.
Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW. Combining radiation and immunotherapy: a new systemic therapy for solid tumors?. Cancer Immunol Res 2(9):831-838, 2014. PMID: 25187273.
Cortez MA, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin GA, Komaki R, Giri DK, Quini CC, Wolfe T, Peltier HJ, Bader AG, Heymach JV, Meyn RE, Welsh JW. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther 22(8):1494-1503, 2014. PMID: 24791940.
Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael RA, Hong DS, Komaki R, Welsh JW. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys 89(5):1084-1091, 2014. e-Pub 2014. PMID: 25035212.
Cuellar SL, Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, Lee JH, Swisher SG, Correa AM, Erasmus JJ, Hofstetter WL. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?. J Thorac Oncol 9(8):1202-1206, 2014. PMID: 25157774.
Li Q, Swanick CW, Allen PK, Gomez DR, Welsh JW, Liao Z, Balter PA, Chang JY. Stereotactic ablative radiotherapy (SABR) using 70Gy in 10 fractions for non-small cell lung cancer: Exploration of clinical indications. Radiother Oncol 112(2):256-61, 2014. PMID: 25108807.
Amini A, Byers LA, Welsh JW, Komaki RU. Progress in the management of limited-stage small cell lung cancer. Cancer 120(6):790-798, 2014. PMID: 24327434.
Massarelli E, Papadimitrakopoulou V, Welsh JW, Tang C, Tsao AS. Immunotherapy in lung cancer. Transl Lung Cancer Res 3(1):53-63, 2014. PMID: 25806281.
Amini A, Ajani J, Komaki R, Allen PK, Minsky BD, Blum M, Xiao L, Suzuki A, Hofstetter W, Swisher S, Gomez D, Liao Z, Lee JH, Bhutani MS, Welsh JW. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol 21(1):306-314, 2014. e-Pub 2013. PMID: 24197760.
Yang J, Amini A, Williamson R, Zhang L, Zhang Y, Komaki R, Liao Z, Cox J, Welsh JW, Court L, Dong L. Automatic contouring of brachial plexus using a multi-atlas approach for lung cancer radiotherapy. Pract Radiat Oncol 3(4):e139-e147, 2013. PMID: 24273627.
Evans JD, Gomez DR, Chang JY, Gladish GW, Erasmus JJ, Rebueno N, Banchs J, Komaki R, Welsh JW. Cardiac (18)F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiother Oncol 109(1):82-88, 2013. PMID: 24016676.
Chang JY, Liu YH, Zhu Z, Welsh JW, Gomez DR, Komaki R, Roth JA, Swisher SG. Stereotactic ablative radiotherapy: a potentially curable approach to early-stage multiple primary lung cancer. Cancer 119(18):3402-3410, 2013. PMID: 23798353.
Shirvani SM, Juloori A, Allen PK, Komaki R, Liao Z, Gomez D, O'Reilly M, Welsh JW, Papadimitrakopoulou V, Cox JD, Chang JY. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys 87(1):139-147, 2013. PMID: 23920393.
Francis AM, Sepesi B, Correa AM, Blum MA, Erasmus JJ, Lee JH, Maru DM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Welsh JW, Swisher SG, Hofstetter WL, University of Texas MD Anderson Esophageal Cancer Group. The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma. Ann Surg 258(3):500-507, 2013. PMID: 24022442.
Murphy CC, Correa AM, Ajani JA, Komaki RU, Welsh JW, Swisher SG, Hofstetter WL. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg 17(8):1359-1369, 2013. PMID: 23715646.
Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52(5):1002-1009, 2013. PMID: 22950385.
Benveniste MF, Welsh JW, Godoy MC, Betancourt SL, Mawlawi OR, Munden RF. New era of radiotherapy: an update in radiation-induced lung disease. Clin Radiol 68(6):e275-e290, 2013. PMID: 23473474.
Cheedella KS, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welsh JW, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol, 2013. PMID: 23247658.
Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 24(5):1312-1319, 2013. PMID: 23300016.
Bhardwaj V, Cascone T, Cortez MA, Amini A, Evans J, Komaki RU, Heymach JV, Welsh JW. Modulation of c-met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer 119(10):1768-1775, 2013. PMID: 23423860.
Evans JD, Gomez DR, Amini A, Rebueno N, Allen PK, Martel MK, Rineer JM, Ang KK, McAvoy S, Cox JD, Komaki R, Welsh JW. Aortic dose constraints when reirradiating thoracic tumors. Radiother Oncol 106(3):327-332, 2013. PMID: 23453540.
Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer. J Clin Oncol 31(7):895-902, 2013. PMID: 23341526.
Gomez DR, Hong DS, Allen PK, Welsh JW, Mehran RJ, Tsao AS, Liao Z, Bilton SD, Komaki R, Rice DC. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol 8(2):238-245, 2013. PMID: 23247629.
Welsh JW, Amini A, Ciura K, Nguyen N, Palmer M, Soh H, Allen PK, Paolini M, Liao Z, Bluett J, Mohan R, Gomez D, Cox JD, Komaki R, Chang JY. Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Med Dosim 38(4):442-7, 2013. PMID: 24200220.
Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh JW, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer 48(18):3396-3404, 2012. PMID: 22853875.
Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, Buchholz TA, Smith BD. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 84(5):1060-1070, 2012. PMID: 22975611.
Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh JW, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 23(10):2638-2642, 2012. PMID: 22831985.
Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Mehran RJ, Rice DC, Suzuki A, Lee JH, Bhutani MS, Welsh JW, Lin SH, Maru DM, Swisher SG, Ajani JA. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus 25(7):614-622, 2012. PMID: 22150920.
Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh JW, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2(9):798-811, 2012. PMID: 22961666.
Bhardwaj V, Zhan Y, Cortez MA, Ang KK, Molkentine D, Munshi A, Raju U, Komaki R, Heymach JV, Welsh J. c-MET inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. J Thorac Oncol 7(8):1211-1217, 2012. PMID: 22617250.
Amini A, Xiao L, Allen PK, Suzuki A, Hayashi Y, Liao Z, Hofstetter W, Crane C, Komaki R, Bhutani MS, Lee JH, Ajani JA, Welsh JW. Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys 83(2):e231-e239, 2012. PMID: 22436793.
Welsh JW, Settle S, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 118(10):2632-2640, 2012. e-Pub 2011. PMID: 22565611.
Yin M, Liao Z, Yuan X, Guan X, O'Reilly MS, Welsh JW, Wang LE, Wei Q. Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer Sci 103(5):945-950, 2012. PMID: 22320189.
Amini A, Yang J, Williamson R, McBurney ML, Erasmus J, Allen PK, Karhade M, Komaki R, Liao Z, Gomez D, Cox JD, Dong L, Welsh JW. Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. Int J Radiat Oncol Biol Phys 82(3):e391, 2012. PMID: 22284035.
Harvin JA, Lahat G, Correa AM, Lee J, Maru D, Ajani J, Marom EM, Welsh JW, Bhutani MS, Walsh G, Roth J, Mehran R, Vaporciyan A, Rice D, Swisher S, Hofstetter W. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins. J Thorac Cardiovasc Surg 143(2):412-420, 2012. e-Pub 2011. PMID: 22172216.
Welsh JW, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, Cox JD, Komaki R. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys 82(1):468-474, 2012. e-Pub 2010. PMID: 21123005.
Kim JY, Correa AM, Vaporciyan AA, Roth JA, Mehran RJ, Walsh GL, Rice DC, Ajani JA, Maru DM, Bhutani MS, Welsh JW, Marom EM, Swisher SG, Hofstetter WL. Does the timing of esophagectomy after chemoradiation affect outcome?. Ann Thorac Surg 93(1):207-212; discussion 212-213, 2012. e-Pub 2011. PMID: 21962263.
Cortez MA, Welsh JW, Calin GA. Circulating microRNAs as non-invasive biomarkers in breast cancer. Recent Results Cancer Res 195:151-61, 2012. PMID: 22527502.
Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology 82(2):108-113, 2012. PMID: 22328056.
Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh JW, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology 83(5):300-304, 2012. PMID: 22964903.
Chang JY, Liu H, Balter P, Komaki R, Liao Z, Welsh JW, Mehran RJ, Roth JA, Swisher SG. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol 7(152):1-10, 2012. PMID: 22963661.
Welsh JW, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, Dong L, Zhu XR, Likhacheva A, Liao Z, Hofstetter WL, Ajani JA, Cox JD. Intensity-modulated proton therapy further reduces normal-tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys 81(5):1336-1342, 2011. PMID: 21470796.
Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 117(21):4823-4833, 2011. PMID: 21456015.
Welsh JW, Thomas J, Shah D, Allen PK, Wei X, Mitchell K, Gao S, Balter P, Komaki R, Chang JY. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 81(1):91-96, 2011. e-Pub 2010. PMID: 20542388.
Ajani JA, Blum MA, Welsh JW, Hofstetter WL, Swisher SG. Celebrate or calibrate? We say calibrate. J Clin Oncol 29(19):2732-2733, 2011. e-Pub 2011. PMID: 21606421.
Welsh JW, Amini A, Likhacheva A, Erasmus J J, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, Ajani JA. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep 13(3):157-167, 2011. PMID: 21365188.
Turner LM, Howard JA, Dehghanpour P, Barrett RD, Rebueno N, Palmer M, Vedam S, Klopp A, Komaki R, Welsh JW. Exploring the feasibility of dose escalation positron emission tomography-positive disease with intensity-modulated radiation therapy and the effects on normal tissue structures for thoracic malignancies. Med Dosim 36(4):383-388, 2011. PMID: 21144734.
Nguyen NP, Bishop M, Borok TJ, Welsh JW, Hamilton R, Cohen D, Nguyen LM, Vincent VH. Pattern of failure following chemoradiation for locally advanced non-small cell lung cancer: potential role for stereotactic body radiotherapy. Anticancer Res 30(3):953-961, 2010. PMID: 20393019.
Welsh JW, Ellsworth RK, Kumar R, Fjerstad K, Martinez J, Nagel RB, Eschbacher J, Stea B. Rad51 protein expression and survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 74(4):1251-1255, 2009. PMID: 19545791.
Olsen CC, Welsh JW, Kavanagh BD, Franklin W, McCarter M, Cardenes HR, Gaspar LE, Schefter TE. Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 73(5):1414-1424, 2009. PMID: 18990508.
Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B. The c-MET receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol 4(69):69, 2009. e-Pub 2009. PMID: 20028557.
Nguyen NP, Garland L, Welsh JW, Hamilton R, Cohen D, Vinh-Hung V. Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma. Cancer Treat Rev 34(8):719-727, 2008. e-Pub 2008. PMID: 18657910.
Nguyen NP, Vos P, Lee H, Borok TL, Karlsson U, Martinez T, Welsh JW, Cohen D, Hamilton R, Nguyen N, Nguyen LM, Vinh-Hung V. Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer. Oncology 75(3-4):186-191, 2008. e-Pub 2008. PMID: 18841033.
Welsh JW, Abhay S, Gabayan A, Green SB, Lustig R, Burri S, Kwong E, Baldassarre S. GliaSite radiotherapy boost as part of initial treatment of malignant gliomas: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 68(1):159-165, 2007.
Xu L, Corcoran RB, Welsh JW, Pennica D, Levine AJ. WISP-1 is a Wnt-1 and beta-catenin-responsive oncogene. Genes Dev 14(5):585-595, 2000. PMID: 10716946.
Pennica D, Swanson T, Welsh JW, Roy M, Lawrence D, Lee J, Brush J, Taneyhill LA, Deuel B, Lew M, Watanabe C, Cohen RL, Melhem M, Finley G, Quirke P, Goddard AD, Hillan KJ, Gurney AL, Botstein D, Levine AJ. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A 95(25):14717-14722, 1998. PMID: 9843955.

Manuals, Teaching Aids, Other Teaching Publications

Laino C, Welsh J. Stereotactic body radiation therapy called new standard of care for inoperable early lung cancer. Oncology Times, 2009.

Editorials

Welsh JW, McGovern SL, Wefel JS, Komaki R, Brown PD, Soh HE. Reply to V.R. Bhatt et al and M.C. Chamberlain. J Clin Oncol 31(25):3165-3166, 2013. PMID: 23943829.

Abstracts

Nguyen QN, Lu Y, Tang C, Chance WW, Mehran R, Balter P, Welsh JW, Hahn SM, Jeter MD, Komaki RU, Gomez DR, Chang JY, Liao Z. Stereotactic Ablative Body Radiation for Pulmonary Metastases: Should We Consider Dose Escalation for More Unresponsive Histologies?. Int J Radiat Oncol Biol Phys 98(1):237, 2017. PMID: 28587012.
Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, Kelnar K, Martin D, Komaki R, Gomez DR, Krishnan S, Calin GA, Bader AG, Welsh JW. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst 108(1). e-Pub 2015.
Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 7(9):967-980, 2015.
Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK. Adding erlotinib to chemoradiation improves overall survival but not progression-free survival in stage III non-small Cell lung cancer. Int J Radiat Oncol Biol Phys 92(2):317-324, 2015.
Seyedin SN, Tang C, Welsh JW. Author's view: radiation and immunotherapy as systemic therapy for solid tumors. OncoImmunology 4(3), 2015. e-Pub 2015.
Swanick CW, Lin SH, Sutton J, Naik NS, Allen PK, Levy LB, Liao Z, Welsh JW, Komaki R, Chang JY, Gomez DR. Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clin Lung Cancer 16(2):156-63, 2015. e-Pub 2014. PMID: 25467928.
Nguyen Q, Tang C, Chance WW, Balter P, Welsh JW, Gomez DR, Komaki RU, Liao Z, Chang JY, Mehran RJ. Outcomes, Patterns of Failures and Toxicity for patients diagnosed with Pulmonary Metastases treated with Stereotactic Body Ablative Radiotherapy (SABR). ASTRO 2015, 2015.
Tang C, Naing A, De Groot P, Chang J, Massarelli E, Parkhurst KL, Erdman D, Barrientes S, Fok J, Subbiah V, Fu S, Tsimberidou A, Karp D, Gomez D, Heymach JV, Hahn SM, Komaki R, Hong D, Welsh JW. Phase 1 Study of ipilimumab and Sterotactic Radiation Targeting Liver or Lung Lesions in Patients with Advanced Malignancies. Astro Abstract 2015, 2015.
Chance WW, Nguyen Q, Mehran R, Welsh JW, Gomez DR, Balter P, Komaki R, Liao Z, Chang J. Stereotactic ablative radiotherapy for treatment of adrenal gland metastasis: toxicity, patterns of failure, and factors impacting outcomes. Proceedings of 2015 ASTRO Annual Meeting, 2015.
Gavini H, Sheu-Woc W, Singh A, Ross WA, Ajani JA, Bhutani MS, Weston BR, Hofstetter WL, Davila ML, Raju GS, Welsh J, Lee J. Is a repeat endoscopy (EGD) necessary when referred for staging of newly diagnosed esophageal cancer? : A comparison of cancer specialty institution (CSI) with other institutions (OSF). Gastroenterol 146(5):S511-S512, 2014.
Cortez MA, Yang C, Byers L, Diao L, Allen T, Giri U, Wang J, Welsh J, Heymach J. Reciprocal regulation of MYC and LKB1 modulates cell survival and differentiation in lung cancer. Proceedings of the American Association for Cancer Research, 2014.
Chang J, Liu YH, Zhu ZH, Welsh J, Gomez D, Komaki R, Roth JA, Swisher SG,. Stereotactic ablative radiotherapy: a potentially curable approach to multiple primary lung cancer. J Thoracic Oncol 8(2):S1133, 2013.
Komaki R, Allen P, Wei X, Blumenschein G, Tang XM, Lee J, Welsh J, Wistuba II, Liu DD, Hong WK. Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III non-small cell lung cancer: a prospective phase II study. J Thoracic Oncol 8(2):S136, 2013.
Komaki R, Allen P, Wei X, Gomez D, Heymach JV, Welsh J, O'Reilly M, Takahashi O, Lin SH, Cox JD. Duration of thoracic radiotherapy with concurrent chemotherapy is important for outcome of patients with limited-stage small cell lung cancer (L-SCLC). J Thoracic Oncol 8(2):S336, 2013.
Swanick CW, Naik NS, Liao Z, Welsh J, Komaki R, Chang JY, O'Reilly M, Lin SH, Gomez D. Toxicity and local control with intensity-modulated radiation therapy (IMRT) using a simultaneous integrated boost (SIB) hypofractionated approach for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 87(2):S508, 2013.
Komaki R, Allen P, Wei X, Gomez D, Heymach J, Welsh J, O’Reilly M, Lin S, Cox JD. Duration of thoracic radiotherapy with concurrent chemotherapy is important for the outcome of patients with limited stage small cell lung cancer (LS-SCLC). Int J Radiat Oncol Biol Phys 87(2):S537, 2013.
Naik NS, Swanick CW, Wei C, Liao Z, Welsh JW, Komaki R, Chang JY, O’Reilly MS, Gomez D, Lin SH. High local failure rates despite dose escalation may support the metastatic self-seeding phenomena in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 87(2):S519, 2013.
Soh HE, Bhardwaj V, Cortez MA, Allen PK, Heymach J, Li X, Meyn R, Xia D, Gomez DR, Skinner HJ, Liao Z, Komaki R, Welsh J. Elevated serum HGF is associated with radioresistance and local recurrence in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 87(2):S652, 2013.
Evans JD, Gomez DR, Chang JY, Gladish GW, Erasmus JJ, Rebueno N, Banchs J, Komaki R, Welsh J. Cardiac isodose distributions and increases in focal 18F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic ablative radiotherapy. Int J Radiat Oncol Biol Phys 87(2):S645, 2013.
Xu T, Gomez D, O’Reilly M, Levy LB, Welsh J, Lin SH, Komaki R, Liu Z, Wei Q, Liao Z. Circulating miR-155 predicts for acute esophageal toxicity in patients with non-small cell lung cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 87(2):S93-S94, 2013.
Wei X, Allen PK, Gomez D, Kotamarti J, Heymach J, Welsh J, O’Reilly M, Lin SH, Cox JD, Komaki R. Improved 5-year disease free-survival and distant metastasis-free survival for patients with limited-stage small cell lung cancer who had 18F-fluorodeoxyglucose positron emission tomography (PET) or PET/CT before chemoradiation therapy. Int J Radiat Oncol Biol Phys 87(2):S536, 2013.
Singh A, Ladha HS, Bhattacharya A, Welsh J, Qiao W, Krishna SG, Ross WA, Bhutani MS, Ajani JA, Hofstetter WL, Swisher SG, Lee JH. Is dilation necessary to complete EUS staging for esophageal cancer?. Gastrointest Endosc 77(5):AB361, 2013.
Komaki R, Allen P, We Xi, Blumenschein G, Wistuba I, Lee J, Welsh J, O’Reilly M, Tang X, Hong W. Phase II trial of erotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer has shown a favorable response profile. Int J Radiat Oncol Biol Phys 84(35):S68, 2012.
McAvoy S, Komaki R, Allen P, Rineer J, Liao Z, Chang J, Welsh J, Palmer M, Cox J, Gomez D. Reirradiation with proton beam therapy or intensity modulated radiation therapy for non-small cell lung cancer: an institutional experience. Int J Radiat Oncol Biol Phys 84(35):S608, 2012.
Fakhreddine M, Liao Z, Zhuang Y, Bhardwaj V, Tucker S, Skinner H, Heymach J, Gomez D, Komaki R, Welsh J. Poor glycemic control during radiochemotherapy contributes to reduced local control and overall survival in patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 84(35):S69, 2012.
Welsh J, Likacheva A, Byers LA, Bhardwaj V, Diao L, Wang J, Ang KK, Romaki R, Kim E, Heymach JV. Implications of KRAS mutations on outcomes in non-small cell lung cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 84(35):S70, 2012.
Gomez DR, Liao K, Chang JY, Liao Z, Shirvani SM, Komaki R, Welsh J, Heymach JV, Swisher SG, Smith BD.. Treatment modality and other prognostic factors for overall survival in stage III non-small cell lung cancer: a population-based analysis. Int J Radiat Oncol Biol Phys 84(35):S540, 2012.
Gomez DR, Liao K, Chang JY, Liao Z, Shirvani SM, Komaki R, Welsh J, Swisher SG, Heymach JV, Smith BD. Patient selection for treatment modality in stage III non-small cell lung cancer: a population-based analysis. Int J Radiat Oncol Biol Phys 84(35):S540, 2012.
Wang H, Gomez DR, Komaki R, Welsh J, O’Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Liao Z. Improved survival outcomes in non-small cell lung cancer patients with incidental concurrent use of beta-blockers and definitive radiation therapy. Int J Radiat Oncol Biol Phys 84(35):S587, 2012.
Zhuang Y, Gomez DR, Komaki R, O’Reilly MS, Welsh J, Lin SH, Chang JY, Jeter M, Liao Z. Prognostic factors for overall survival in stage IIIA/IIIB non-small cell lung cancer after definitive (chemo)radiation therapy. Int J Radiat Oncol Biol Phys 84(35):S591, 2012.
Juloori A, Shirvani SM, Allen PK, Komaki R, Liao Z, Welsh J, Gomez DR, Heymach JV, Chang JY. Limited-stage small cell lung cancer in the contemporary period: impact of new technologies on outcomes. Int J Radiat Oncol Biol Phys 84(35):S592, 2012.
Shirvani SM, Juloori A, Gomez DR, Allen PK, Komaki R, O’Reilly MS, Liao Z, Welsh J, Papdimitrakopoulou V, Chang JY. Patterns of failure for limited-stage small cell lung cancer following definitive radiation in the modern era. Int J Radiat Oncol Biol Phys 84(35):S595, 2012.
Komaki R, Allen P, Wei X, Blumenschein G, Wistuba I, Lee J, Welsh J, O'Reilly M, Tang X, Hong W. Phase II trial of erotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer has shown a favorable response profile. J Thorac Oncol 7(15):S279, 2012.
Komaki R, Allen P, Wei X, Gomez D, Fossella F, Heymach J, Welsh J, O’Reilly M, Lin S, Cox JD. Thoracic radiotherapy within 6 weeks with concurrent chemotherapy improved outcome of patients with limited stage small cell lung cancer (LS-SCLC). J Thorac Oncol 7(15):S217, 2012.
Skinner H, McCurdy M, Echeverria A, Lin S, Welsh J, O'Reilly MO, Hofstetter W, Ajani J, Komaki R, Guerrero T. Metformin use is associated with improved response to neoadjuvant chemoradiation in esophageal adenocarcinoma. J Thorac Oncol 7(15):S240, 2012.
Shirvani SM, Juloori A, Gomez D, Allen P, Komaki R, O'Reilly MO, Liao Z, Welsh J, Papadimitrakopoulou V, Chang JY. Patterns of failure for limited-stage small cell lung cancer following definitive radiotherapy in the modern era. J Thorac Oncol 7(15):S279, 2012.
Juloori A, Shirvani S, Allen P, Komaki R, Liao Z, Welsh J, Gomez D, Heymach JV, Chang JY. Limited-stage small cell lung cancer in the contemporary period: impact of new technologies on outcomes. J Thorac Oncol 7(15):S329, 2012.
Blum M, Hayashi Y, Xiao L, Suzuki A, Sabloff B, Maru D, Taketa T, Welsh JW, Lin S, Lee J, Bhutani M, Weston B, Hofstetter W, Swisher S, Ajani J. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with esophageal cancer (EC). J Clin Oncol 30(suppl):abstr e14547, 2012.
Suzuki A, Xiao L, Taketa T, Blum M, Welsh J, Lin S, Weston B, Lee J, Bhutani M, Rice D, Mehran R, Maru, Erasmus J, Hofstetter W, Swisher S, Ajani J. Customization of treatment for patients with esophageal adenocarcinoma (EAC) who achieve clinical complete response (cCR) after chemoradiation using initial standardized uptake value (iSUV) of 18f-fluorodeoxyglucose PET. J Clin Oncol 30(suppl):abstr 4069, 2012.
Taketa T, Correa A, Suzuki A, Blum M, Lee J, Welsh J, Lin S, Maru D, Erasmus J, Bhutani M, Weston B, Rice D, Swisher S, Hofstetter W, Ajani J. Outcome of 58 trimodality-eligible esophagogastric cancer (EC) patients who achieved clinical complete response (cCR) after preoperative chemoradiation but then declined surgery. J Clin Oncol 30(suppl):abstr 4078, 2012.
Cheedella S, Suzuki A, Correa A, Hofstetter W, Mehran R, Rice D, Maru D, Vaporciyan A, Taketa T, Blum M, Welsh J, Lin S, Lee J, Bhutani M, Weston B, Walsh G, Swisher S, Ajani J. Association of clinical complete response (cCR) after preoperative chemoradiation and pathological complete response (pathCR) in patients with gastroesophageal cancer (GEC) and indispensability of trimodality therapy (TMT). J Clin Oncol 30(suppl):abstr 4086, 2012.
Amini A, Welsh J, Allen P, Xiao L, Suzuki A, Hayashi Y, Blum M, Hofstetter W, Liao Z, Lee J, Bhutani M, Komaki R. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. J Clin Oncol 30(suppl):abstr e14669, 2012.
Byers L, Nilsson M, Masrorpour F, Wang J, Diao L, Bhardwaj V, Welsh J, Girard L, Coombes K, Weinstein J, Lippman L, Glisson B, Minna J, Heymach J. Investigation of PARP1 as a therapeutic target in small cell lung cancer. J Clin Oncol 30(suppl):abstr 7096, 2012.
Shirvani S, Jiang J, Chang J, Gomez D, Welsh J, Swisher S, Buchholz T, Smith B. Comparative effectiveness of five treatment strategies for early-stage non-small cell lung cancer in the elderly. J Clin Oncol 30(suppl):abstr 7062, 2012.
Cortez M, Bhardwaj V, Zhan Y, Byers L, Calin G, Heymach J, Welsh J. Mir-200c overexpression radiosensitizes lung cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting, 2012.
Bhardwaj V, Likhacheva A, Byers L, Komaki R, Kim E, Heymach J, Welsh J. Establishing role of KRAS mutation on NSCLC radio-sensitivity. Proceedings of the American Association for Cancer Research Annual Meeting, 2012.
Benveniste M, Betancourt S, Godoy M, Mawlawi O, Welsh J, Munden R. New era of radiotherapy: an update in radiation-induced lung disease. Proceedings of the Scientific Assembly and Annual Meeting of the Radiological Society of North America, 2011.
Komaki R, Blumenschein GR, Wistuba II, Lee J, Allen PK, Wei X, Welsh J, O'Reilly MS, X Tang, Hong W. The phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer has shown a favorable response profile. Int J Radiat Oncol Biol Phys 81(2s):S591-S592, 2011.
Welsh J, Kim E, Amin A, Allen P, Chang J, Komaki R, Nguyen N, Holt J, Erdman D, Stea B. Phase II safety data of erlotinib with concurrent whole-brain radiation therapy for patients with brain metastasis from non-small cell lung cancer. Int J Radiat Oncol Biol Phys 81(2s):S136, 2011.
Amini A, Welsh JW, Yang J, McBurney ML, Williamson MT, Karhade M, Allen P, Erasmus J, Dong L, Liao Z. Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. Int J Radiat Oncol Biol Phys 81(2s):S110-S111, 2011.
Ciura KT, Welsh J, Nguyen N, Palmer M, Paolini M, Bluett J, Mohan R, Gomez D, Cox JD, Chang J. Evaluating stereotactic body radiotherapy with protons to reduce chect wall dose in the treatment of lung cancer. Int J Radiat Oncol Biol Phys 81(2s):S87, 2011.
Gomez DR, Amin MV, Crawford C, Welsh J, Chang JY, Zhu XR, Liao Z, Komaki R, Cox JD, Mohan R. A comparison of strategies to account for bowel filling in patients treated with proton therapy for locally advanced distal esophageal cancer: a planning study. Int J Radiat Oncol Biol Phys 81(2s):S883, 2011.
Ajani JA, Wang X, Hayashi Y, Maru D, Welsh J,Hofstetter WL, Lee JH, Bhutani MS, Suzuki A, Berry DA, Izzo J. Validated biomarker signatures that predict pathologic response to preoperative chemoradiation therapy (CTRT) with high specificity and desirable sensitivity levels in patients with esophageal cancer (EC). J Clin Oncol 29(suppl):abstr 4027, 2011.
Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Rice DC, Walsh GL, Mehran RJ, Suzuki A, Lee H, Bhutani MS, Lin SH, Welsh J, Maru D, Swisher S, Ajani JA. The association between body mass index and baseline clinical stage of esophageal carcinoma. J Clin Oncol 29(suppl):abstr 4090, 2011.
Welsh J, Amini A, Kim ES, Allen P, Chang JY, Garland LL, Holt J, Erdman D, Komaki R, Stea B. Phase II study of erlotinib with concurrent whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer. J Clin Oncol 29(suppl):abstr 2031, 2011.
Suzuki A, Xiao L, Hayashi Y, Welsh J, Lin SH, Maru D, Hofstetter WL, Mehran RJ, Lee JH, Bhutani MS, Macapinlac HA, Liao ZX, Ajani JA. Prognostic significance of post-treatment standardized uptake value (pSUV) of positron emission tomography (PET) to predict overall survival (OS) and relapse-free survival (RFS) in patients with esophageal or gastroesophageal cancer treated with definitive chemoradiotherapy. J Clin Oncol 29(suppl):abstr 4055, 2011.
Komaki R, Blumenschein GR, Wistuba II, Lee JJ, Allen P, Wei X, Welsh J, O'Reilly M, Herbst S, Tang X, Meyn RLiu D, Hong WK. Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer. J Clin Oncol 29(suppl):abstr 7020, 2011.
Welsh J, Riley B, Palmer MB, Amin MV, Komaki R, Gomez D, Liao Z, Hofstetter WL, Ajani A, Cox JD. Intensity-modulated proton therapy allows dose escalation and normal-tissue sparing in locally advanced distal esophageal tumors. Int J Radiat Oncol Biol Phys 78(3s):S808, 2010.
Likhacheva A, Thomas J, Kim E, Allen P, Komaki R, Cox J, Herbst R, Welsh J. Predictive implications of KRAS and EGFR gene mutation in non-small cell lung cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 78(3s):S128-129, 2010.
Welsh J, Zhan Y, Likhacheva A, Komaki R. Radiation-induced c-MET expression sensitizes lung cancer cells to c-MET antagonists. Eur J Cancer 8(7):162, 2010.
Welsh JW, Thomas J, Wei X, Allen P, Mitchell K, Gao S, Komaki R, Chang J. Skin toxicity and pain in patients treated with stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 75(3s):S61, 2009.
Palmer MB, Vedam S, Komaki R, Welsh J. Intensity modulated radiation therapy (IMRT) benchmarks for thoracic malignancies. Int J Radiat Oncol Biol Phys 75(3s):S476, 2009.
Gao S, Chang JY, Welsh J, Komaki R, Balter P. Influence of the couch and immobilization device used during stereotactic body radiotherapy on skin dose. Int J Radiat Oncol Biol Phys 75(3s):S682, 2009.
Rebueno NC, Welsh JW. Exploring the feasibility of dose escalation with IMRT and the effects on normal tissue structures for thoracic malignancies. Int J Radiat Oncol Biol Phys 75(3s):S458, 2009.
Welsh JW, Ellsworth R, Mahadevan D, Bearss D, Komaki R, Stea B. A c-MET receptor tyrosine kinase inhibitor offers increased radiosensitization in NSCLC after pretreatment with erlotinib. J Thorac Oncol 4(9, s1):S957, 2009.
Takahashi O, Komaki R, Smith P, Ryan A, Jurgensmeier J, Welsh JW, Jacoby JJ, Hosho K, Korshunova M, Erez B, Herbst R, O'Reilly M. MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits tumor growth and progression in an orthotopic human lung adenocarcinoma model with enhanced efficacy when combined with cediranib. J Thorac Oncol 4(9, s1):S593, 2009.
Ellsworth R, Welsh JW, Mahadevan D, Bearrs D, Hsieh D, Fjerstad K, Marsella M, Sanan A, Badrudojja M, Stea B. The radiosensitizing effects of a novel tyrosine kinase inhibitor, MP470 in glioblastoma multiforme stem cells. Int J Radiat Oncol Biol Phys 72(1s):S714-S715, 2008.
Ellsworth R, Welsh JW, Kumar R, Fjerstad K, Green S, Nagle R, Stea B. CD133 expression before and after radiation in glioblastoma multiforme. Proceedings of the American Association for Cancer Research Annual Meeting, 2008.
Schefter TE, Welsh JW, Gaspar L, Kavanagh B.. Normal liver V30% and mean liver dose predicts the maximum normal liver volume reduction after stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys 69(3s):S596, 2007.
Kumar R, Welsh JW, Nagle RB, Green S, Stea BD.. Association between Rad-51 levels and survival in patients with glioblastoma multiforme treated with radiation therapy. Int J Radiat Oncol Biol Phys 69(3s):S63-S64, 2007.
Welsh JW, Mahadevan D, Bearss D, Stea B.. Sensitization of a glioblastoma multiform (GBM) cell line by MP470: a novel c-MET antagonist. Int J Radiat Oncol Biol Phys 69(3s):S100, 2007.
Welsh JW, Mahadevan D, Dougherty G, Stea B.. A c-MET receptor tyrosine kinase inhibitor radiosensitizes glioblastoma cells by reducing dsDNA repair, mediated through decreased Rad-51. Proceedings of the Annual Meeting of the American Radium Society, 2007.
Welsh JW, Garland L, Stea BD, Philip-Norton R. A phase II study to determine the efficacy of tarceva (erlotinib hydrochloride) with concurrent whole brain radiation therapy (WBRT) in patients with brain metastases from non-small cell lung cancer. J Thorac Oncol 2(8):S763, 2007.
Welsh JW, Mahadevan D, Dougherty G, Stea B.. c-MET inhibition radiosensitizes melanoma by inhibiting double strand DNA repair. Int J Radiat Oncol Biol Phys 66(3s):S557-S558, 2006.
Watchman C, Hamilton R, Welsh JW. Implanted marker movements during prostate IMRT. Proceedings of the American Association of Physicists in Medicine Annual Meeting, 2006.
Welsh JW, Gabayan A, Sanan A, Stea B. GliaSite radiotherapy boost as part of initial treatment of malignant gliomas: A multi-institutional analysis. Brachytherapy 5(2):78-79, 2006.
Welsh JW, Gabayan A, Sanan A, Green S, Hass M, Burri S, Bishop M, Stea B. GliaSite radiotherapy boost as part of initial treatment of malignant gliomas: a multi-institutional analysis. Radiother Oncol 78(s1):S89-S90, 2006.

Book Chapters

Bhardwaj V, Cortez A, Fakhreddine M, Welsh J. Biologic principles of radiosensitization. In: Cancer Nanotechnology: Principles and Applications in Radiation Oncology. Taylor and Francis Books, Inc: Boca Raton, FL, 15-24, 2013.
Lin S, Welsh J. Advanced-stage (III-IV) non-small cell lung cancer. In: Radiation Oncology: A Question-Based Review. Lippincott Williams & Wilkins, 209-221, 2010.

Less

Grant & Contract Support

Title:	Treatment of metastatic lung cancer with radiotherapy plus OX40 immunotherapy
Funding Source:	NIH/NCI
Role:	Principal Investigator

Title:	Combining radiotherapy with CSF-1R blockage to enhance anti-tumor activity in solid tumors
Funding Source:	NIH/NCI
Role:	Principal Investigator

Title:	Using radiation plus anti-PD1 immunotherapy to improve CAR T cell targeting of solid tumors
Funding Source:	NIH/NCI
Role:	Principal Investigator

Title:	Targeting tumor-associated macrophages with anti-CSF1R in KRAS mutant tumors to overcome radioresistance in lung cancer
Funding Source:	Lung Cancer Research Foundation
Role:	Principal Investigator

Title:	Using radiation plus anti-PD1 immunotherapy to improve CAR+ T-cell targeting of solid tumors
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Principal Investigator

Title:	Combining anti-OX40 agonist antibody immunotherapy plus radiotherapy to overcome metastatic lung cancer
Funding Source:	GlaxoSmithKline
Role:	Principal Investigator

Title:	Phase l trial of MK-3475 and concurrent chemo/radiation for the elimination of small cell lung cancer
Funding Source:	Merck
Role:	Principal Investigator

Title:	Combining radiation and the immunomodulatory IDO inhibitor INCB024360 to treat lung cancer
Funding Source:	Incyte
Role:	Principal Investigator

Title:	BlockingTGF-β to reduce radiation pneumonitis and enhance abscopal responses in non-small cell lung cancer
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	Principal Investigator

Title:	Using CAR-T and NK cells engineered to deliver IL-12 to expand T cells primed by radiation-induced antigens
Funding Source:	NIH/NCI
Role:	Principal Investigator

Title:	The nanomechanical signature of response to therapy in lung cancers
Funding Source:	Artidis AG
Role:	Principal Investigator

Title:	Combination of radiotherapy with engineered selective agonist of intermediate-affinity IL-2 receptor (RDB 1462) to promote systemic anti-tumor responses
Funding Source:	Alkermes, Inc
Role:	Principal Investigator

Title:	2018-0419 Phase I/II trial of ipilimumab or nivolumab with BMS-986156 and hypofractionated stereotactic radiation therapy in patients with advanced solid malignancies
Funding Source:	Bristol-Meyers Squibb
Role:	Principal Investigator

Title:	Phase II trial of salvage radiation therapy to induce systemic disease regression after progression on systemic immunotherapy
Funding Source:	Varian Medical Systems, Inc
Role:	Principal Investigator

Title:	Testing second generation immunotherapies for systemic and intratumoral combinations to enhance abscopal responses in preclinical models
Funding Source:	Bristol-Meyers Squibb
Role:	Principal Investigator

Title:	NBTXR3 in combination with radiation and immunotherapy
Funding Source:	Nanobiotix S.A
Role:	Principal Investigator

Title:	Preclinical Proposal to Assess the Efficacy of Low-Dose Radiotherapy Combined with Kiromic Biopharma Gamma Delta T Cells
Funding Source:	Kiromic Biopharma
Role:	Principal Investigator

Title:	Combination of Radiotherapy with Anti-CCR8 Targeted Therapy
Funding Source:	Gilead
Role:	Principal Investigator

Title:	SIV/OTC Combination of Radiotherapy with CBL-B inhibitor
Funding Source:	Hot Spot Therapeutics
Role:	Principal Investigator

Title:	Blocking DNA damage response induction of "don’t eat me" signals converts local radiotherapy into systemic immunotherapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-Principal Investigator

Title:	Enhancing Precision and Personalized Treatment through the Combined Approach of High and Low-Dose Radiotherapy and Immunotherapy
Funding Source:	NIH/NCI
Role:	Principal Investigator

Title:	Altering the immune metabolic fitness with low-dose radiotherapy to enhance antitumor responses
Funding Source:	NIH/NCI
Role:	Principal Investigator

CV information above last modified September 22, 2023

James W. Welsh, M.D.

About Dr. Welsh

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Other Appointments/Responsibilities

Institutional Committee Activities

Consultantships

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Editorials

Abstracts

Book Chapters

Grant & Contract Support

Patient Reviews

Related Links

Welsh Laboratory

Help #EndCancer

James W. Welsh, M.D.

About Dr. Welsh

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Other Appointments/Responsibilities

Institutional Committee Activities

Consultantships

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Editorials

Abstracts

Book Chapters

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Welsh Laboratory

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer